(Alliance News) - Tiziana Life Sciences PLC on Friday said it has secured a patent from the United States Patent & Trademark Office covering its proprietary platform technology for the oral administration of Foralumab.
The biotechnology firm said the patent - which will be issued on Tuesday - covers oral administration of the "lyophilized and stabilized free-flowing powder" of Foralumab or any other anti-CD3 monoclonal antibodies contained in enteric-coated capsules for the treatment of human diseases.
Tiziana said the patent allows it to work on drugs for Crohn's, multiple sclerosis and Alzheimer's that can be orally-ingested rather than administered by injection or an intravenous line.
"The granting of this patent on first-in-class formulation technology allows us to work on bringing patients the first non-intravenous or subcutaneous treatment with antibodies to treat major gastrointestinal and neurodegenerative diseases such as Crohn's Disease, pro-MS and Alzheimer's. We believe development of the alternative administration routes of antibodies such as oral, nasal and inhalation could potentially be transformational for immunotherapies," said Founder & Chair Gabriele Cerrone.
Tiziana shares were trading 17% higher at 105.00 pence each on Friday morning in London.
By Ife Taiwo; ifetaiwo@alliancenews.com.
Copyright 2020 Alliance News Limited. All Rights Reserved.